In APL patients, two compounds, arsenic trioxide (ATO) and all-trans retinoic acid (ATRA), were demonstrated to directly target PML-RARα, resulting in a 95% cure rate [105]. The gene discussed is RARA; the disease is acute promyelocytic leukemia.